Responses
Regular and Young Investigator Award Abstracts
Cellular Therapies
274 Development of CTX112 a next generation allogeneic multiplexed CRISPR-edited CART cell therapy with disruptions of the TGFBR2 and Regnase-1 genes for improved manufacturing and potency
Compose a Response to This Article
Other responses
No responses have been published for this article.
